openPR Logo
Press release

Idiopathic Pulmonary Fibrosis (IPF) Pipeline, A Novel Advancement for the Treatment of Cancer

02-27-2017 01:14 PM CET | Health & Medicine

Press release from: P&S Market Research- Pharmaceuticals

Idiopathic Pulmonary Fibrosis (IPF) Pipeline, A Novel

The study analyzed that the IPF pipeline comprised of 97 therapeutic candidates, of which 15 are in Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. Various drugs are being developed as novel and promising therapeutics for the treatment of IPF.

Browse the Report Summary at: www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market
Insights on pipeline segments

As per the findings of research, it was found that around 9% IPF candidate target chemokine, 7% target integrin and 6% of the product candidates target G-protein couple receptor. Other targets comprising 78% of candidates of IPF pipeline include, but not limited to, autotaxin, connective tissue growth factor-associated, fibroblast growth factor, lysyl-oxidase like protein 2 and tissue growth factor beta. Around 55% pipeline therapeutic candidates of IPF are being developed to be administered by oral route, 20% by inhalation route, 12% by intravenous route and 8% by subcutaneous route.

Phase III stage of development consist of only one IPF drug

Thrombomodulin Alfa (ART-123) is under Phase III stage of development by Asahi Kasei Pharma Corporation for the treatment of IPF. It is already marketed in Japan under the name of Recomodulin for the treatment of disseminated intravascular coagulation. Thrombomodulin Alfa is a soluble recombinant human thrombomodulin and inhibits the coagulation process by accelerating the activation of protein C by thrombin. The drug candidate is administered by intravenous route.

Browse Report Sample at: www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market/report-sample

Phase II stage of development is crowded with number of promising drugs

There are total 15 drug candidates in Phase II stage of development for the treatment of IPF. GLPG1690 is under Phase II stage of development by Galapagos NV for the treatment of IPF. The drug candidate targets lysophosphatidic acid 1 (LPA1) receptor also known as autotaxin and inhibits its action. The company plans to disclose the Phase II topline results for IPF in the first half of 2017. In February 2015, Galapagos NV released the Phase I study results for GLPG1690 (NCT02179502). GLPG1690 proved to be safe and well-tolerated over a wide dose range in healthy volunteers. The drug candidate showed favorable pharmacokinetic and pharmacodynamic profile. In this trial, GLPG1690 demonstrated the ability to reduce plasma lipid lysophosphatidic acid (LPA) levels on a sustained basis, implying ATX engagement.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com

347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Idiopathic Pulmonary Fibrosis (IPF) Pipeline, A Novel Advancement for the Treatment of Cancer here

News-ID: 450827 • Views: 310

More Releases from P&S Market Research- Pharmaceuticals

Benign Prostatic Hyperplasia Therapeutics Market - Epidemiology Analysis, Therap …
The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grants
Global Esophageal Cancer Therapeutics Market Analysis, Development and Demand Fo …
Global esophageal cancer therapeutics market is expected to witness significant growth with an increasing awareness regarding cancer treatment and technological advancements. Also, high demand for safe and effective medications and rising prevalence of cancer are driving the growth of the global market. The regulatory bodies such as USFDA, EMA are supporting the growth of the global market by providing funding, designations and grants for speeding up the drug development process. Explore
Pancreatic Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Developm …
The global pancreatic cancer therapeutics market holds numerous opportunities for the key players, as pancreatic cancer is a highly challenging disease among all types of cancer, which has no specific treatment available for it, as of now. Also, growing incidence of cancer and technological advancements are supporting the growth of the global pancreatic cancer therapeutics market growth. Explore Report at: www.psmarketresearch.com/market-analysis/pancreatic-cancer-therapeutics-market Cancer instigates uncountable growth of cells due to some abnormalities
Novel Targets for Breast Cancer Treatment Drive Estrogen Receptor-Positive (ER+) …
Estrogen Receptor-Positive (ER+) breast cancer currently exhibits a pipeline with 46 active drug candidates. ER+ breast cancer pipeline offers novel therapeutic targets for the treatment of breast cancer The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates, of which nine products are in Phase III, 16 products in Phase II, 18 products in Phase I, and three products are in Pre-Clinical stage. The development of

All 5 Releases


More Releases for IPF

LED Fog Lamp Market Overview and Forecast Report by 2026 |Magneti Marelli, Rober …
LOS ANGELES, United States: The global LED Fog Lamp market is analyzed in quite some detail in the report with strong focus on the competitive landscape, segmentation, market dynamics, and regional market expansion. The report includes thorough assessment of the business of key players operating in the global LED Fog Lamp market. With deeper qualitative and quantitative analysis of the global LED Fog Lamp market, the report sheds light on
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market As per the findings of research, it
Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market US$ 3.5 Billion by 2 …
The global idiopathic pulmonary fibrosis treatment market expected to reach US$ 3.5 billion by 2021, growing at CAGR 14.4% over the forecast period 2017-2021, owing to increasing drug prices and rapid approval of new treatments. Visit Idiopathic Pulmonary Fibrosis (IPF) Treatment Market by Treatment Type - Pharmacological Treatment (Pirfenidone (Esbriet), Nintedanib (Ofev), Generic Pirfenidone); Non-pharmacological Treatment (Oxygen Therapy, Pulmonary Rehabilitation, Mechanical Ventilation, Lung Transplantation, Other Non-Pharmacological Treatment); Patients by Disease Severity
Recent Release: Global Idiopathic pulmonary fibrosis (IPF) Market To 2023
MarketResearchReports.Biz presents this most up-to-date research on "Idiopathic pulmonary fibrosis (IPF)- Epidemiology Forecast To 2023" Idiopathic pulmonary fibrosis (IPF) - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Idiopathic pulmonary fibrosis (IPF) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Idiopathic pulmonary fibrosis (IPF) prevalent or incident cases segmented by age, sex and
Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market F …
DelveInsight is a leading Business Consultant and Market Research Firm which has become the knowledge partner for biotechnology and pharmaceutical companies by providing competitive intelligence information which aids them to strategize and discover the target areas & potential customers for their products. DelveInsight expertise has expanded from an initial focus on Pipeline & Marketed Reports to Market Forecasting and Epidemiology Reports. Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology
IPF Organizing Two Industrial Trade Shows in Kolkata in November
IPFonline Ltd is organizing two concurrent industrial trade fairs in Kolkata from November 18th to November 21st 2010. 1. Engeetech - An industrial products, engineering and technology trade fair http://engeetechkolkata.ipftradefairs.com/ 2. BACE - A Building, Architecture, Construction and Engineering Products trade fair http://bace.ipftradefairs.com/ As of yesterday 152 exhibitors have committed to exhibit at Engeetech and over 75 have committed to exhibit at BACE. Both the trade fairs will be held concurrently at